Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer.

Nature communications·2026
Same author

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.

Blood·2026
Same author

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.

Nature genetics·2026
Same author

Hybrid Systems Modeling of Donor T-Cell Responses and Graft-Versus-Host-Disease After Posttransplantation Cyclophosphamide Administration.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Robust predictors for drug response of patients with acute myeloid leukemia.

PloS one·2026
Same author

KGBN: Augmenting and optimizing logical gene regulatory networks using knowledge graphs.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Mutation Patterns Predict Drug Sensitivity in Acute Myeloid Leukemia.

Guangrong Qin1, Jin Dai2,3, Sylvia Chien2,3

  • 1Institute for Systems Biology, Seattle, Washington.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 15, 2024
PubMed
Summary

Genetic mutations in acute myeloid leukemia (AML) predict drug response. Identifying these genomic signatures enables personalized treatment strategies for AML patients.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

83
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 28, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

83
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Genomics
  • Cancer Biology
  • Pharmacogenomics

Background:

  • Acute myeloid leukemia (AML) is characterized by significant genetic heterogeneity, complicating treatment development.
  • Developing targeted therapies requires understanding the genomic underpinnings of drug sensitivity and resistance.

Purpose of the Study:

  • To identify genomic signatures for predicting drug response in AML.
  • To elucidate the genetic basis of drug resistance and sensitivity.
  • To provide valuable genomic resources for the AML research community.

Main Methods:

  • Targeted sequencing and high-throughput drug screening of patient-derived leukemia cells.
  • Single-cell genomic profiling to analyze intra-patient heterogeneity.
  • Machine learning and statistical analyses to identify predictive mutation patterns.
  • Integration of large public genomic datasets.

Main Results:

  • Identified specific genetic signatures correlating with sensitivity or resistance to various therapeutic agents.
  • Discovered five distinct co-occurring mutation groups within AML.
  • Single-cell analysis revealed the presence of subclones with co-occurring variants.
  • Mutation patterns accurately predicted sensitivity to certain drug classes, like MEK inhibitors for RAS-mutated AML.

Conclusions:

  • Gene mutation patterns are crucial for predicting drug response in AML.
  • This study provides a framework for classifying AML patients based on mutations to guide drug sensitivity predictions.
  • The findings support the development of precision medicine approaches for AML treatment.